News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
TRANSCENTA-B: Positive Interim Data from ozekibart Mid-stage Study; Greater China Plan Under Evaluation
TRANSCENTA-B (06628.HK) announced that its partner Inhibrx Biosciences, Inc. (INBX.US) recently reported positive updated interim data from its Phase 1/2 study evaluating ozekibart...
Reset
Send
The window will close in 5 seconds
TRANSCENTA-B: Positive Interim Data from ozekibart Mid-stage Study; Greater China Plan Under Evaluation
Close
Recommend
3
Positive
2
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

TRANSCENTA-B (06628.HK)  +0.020 (+1.370%)   announced that its partner Inhibrx Biosciences, Inc. (INBX.US)      recently reported positive updated interim data from its Phase 1/2 study evaluating ozekibart (INBRX-109) in combination with FOLFIRI in patients with locally advanced or metastatic, unresectable colorectal cancer (CRC). Inhibrx also announced the submission of a Biologics License Application (BLA) to the FDA for ozekibart in conventional chondrosarcoma in April 2026.

Transcenta holds the exclusive rights to develop and commercialize ozekibart (INBRX-109) in mainland China, Hong Kong SAR, Macau SAR, and Taiwan region under a license agreement executed through HJB, a wholly owned subsidiary of the Company. In light of these positive developments for ozekibart, Transcenta is actively evaluating its plans in the Greater China region.
(HK stocks quote is delayed for at least 15 mins.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.